BC Partners carves out Synthon

The GP will invest alongside Synthon's founder, Jacques Lemmens, who remains a shareholder in the company.

The company, once carved out from the parent business, will continue to operate under the Synthon brand. BC Partners intends to invest in the expansion of Synthon's product portfolio, as well as its product pipeline, and enter into new markets.  

The transaction is subject to regulatory approval and is expected to close in the coming months.

The GP is currently investing via its BC European Capital X fund, closed in January this year on €7bn. The vehicle typically targets companies with an enterprise value in excess of €300m.

Company
Founded in 1991 and headquartered in Nijmegen, Synthon focuses on developing, manufacturing and licensing complex generics and hybrid medicines for patients around the world.

It employs 1,600 people and generated a €268m turnover in 2018.

People
BC Partners – Mark Hersee (partner).
Synthon – Jacques Lemmens (founder); Edwin de Rooij (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Benelux
• Healthcare
• Netherlands
• BC Partners